Table 1: Demographic characteristics of patients participating in olanzapine and risperidone groups.

VariablesOlanzapine
()
Risperidone
()
95% CI

Age, y36.89 ± 3.5238.44 ± 4.911.2830.205−0.763, 3.481
Age at onset, y22.48 ± 3.7423.62 ± 4.910.9230.360−1.25, 3.17
Duration of illness, y6.83 ± 1.636.39 ± 1.580.9690.337−2.28, 3.24
Number of prior episodes
Mean ± SD
7.18 ± 2.136.82 ± 1.510.650.51−1.46, 0.74
Baseline SAPS63.61 ± 3.8662.19 ± 4.111.3790.1731−0.64, 3.48
Baseline SANS46.26 ± 3.3746.83 ± 3.75−0.6190.5382−2.41, 1.27
Baseline SAI3.49 ± 0.613.51 ± 1.03−0.0920.9274−0.46, 0.42
Baseline SAS0.35 ± 0.760.35 ± 0.760.0001.0000−0.39, 0.39
Baseline CGI-S3.65 ± 1.163.25 ± 0.121.8790.0653−0.03, 0.83

SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for Assessment of Negative Symptoms; CGI-S: Clinical Global Impressions-Severity Scale; SAI: Schedule for Assessment of Insight; and SAS: Simpson Angus Scale.